Evidence map›Paper›PMID 25426116›Full record

ArticleFrontiers in immunology2014

The progression of cell death affects the rejection of allogeneic tumors in immune-competent mice - implications for cancer therapy.

Ricardo A Chaurio, Luis E Muñoz, Christian Maueröder, Christina Janko, Thomas Harrer, Barbara G Fürnrohr, Michael Niederweis, Rostyslav Bilyy, Georg Schett, Martin Herrmann and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Eicosanoid regulation of debris-stimulated metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Dying autologous cells as instructors of the immune system.Clinical and experimental immunology · 2015
    Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ricardo A ChaurioDepartment of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany.
Luis E MuñozDepartment of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany.
Christian MaueröderDepartment of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany ; Department of Biology, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany.
Christina JankoDepartment of Otorhinolaryngology, Head and Neck Surgery, Section for Experimental Oncology and Nanomedicine (SEON), University Hospital Erlangen , Erlangen , Germany.
Thomas HarrerDepartment of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany.
Barbara G FürnrohrDivision of Molecular Immunology, Department of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany ; Division of Biological Chemistry, Medical University Innsbruck , Innsbruck , Austria.
Michael NiederweisDepartment of Microbiology and Biochemistry, University of Alabama at Birmingham , Birmingham, AL , USA.
Rostyslav BilyyInstitute of Cell Biology, National Academy of Sciences of Ukraine , Lviv , Ukraine.
Georg SchettDepartment of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany.
Martin HerrmannDepartment of Internal Medicine 3, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany.
Christian BerensDepartment of Biology, Friedrich-Alexander University of Erlangen-Nuremberg , Erlangen , Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large amounts of dead and dying cells are produced during cancer therapy and allograft rejection. Depending on the death pathway and stimuli involved, dying cells exhibit diverse features, resulting in defined physiological consequences for the host. It is not fully understood how dying and dead cells modulate the immune response of the host. To address this problem, different death stimuli were studied in B16F10 melanoma cells by regulated inducible transgene expression of the pro-apoptotic active forms of caspase-3 (revCasp-3), Bid (tBid), and the Mycobacterium tuberculosis-necrosis inducing toxin (CpnTCTD). The immune outcome elicited for each death stimulus was assessed by evaluating the allograft rejection of melanoma tumors implanted subcutaneously in BALB/c mice immunized with dying cells. Expression of all proteins efficiently killed cells in vitro (>90%) and displayed distinctive morphological and physiological features as assessed by multiparametric flow cytometry analysis. BALB/c mice immunized with allogeneic dying melanoma cells expressing revCasp-3 or CpnTCTD showed strong rejection of the allogeneic challenge. In contrast, mice immunized with cells dying either after expression of tBid or irradiation with UVB did not, suggesting an immunologically silent cell death. Surprisingly, immunogenic cell death induced by expression of revCasp-3 or CpnTCTD correlated with elevated intracellular reactive oxygen species (ROS) levels at the time point of immunization. Conversely, early mitochondrial dysfunction induced by tBid expression or UVB irradiation accounted for the absence of intracellular ROS accumulation at the time point of immunization. Although ROS inhibition in vitro was not sufficient to abrogate the immunogenicity in our allo-immunization model, we suggest that the point of ROS generation and its intracellular accumulation may be an important factor for its role as damage associated molecular pattern in the development of allogeneic responses.

Indexed as

apoptosiscancercaspase-3DAMPsimmunogenicitynecrosisROStBid

Identifiers

PMID25426116
PMCPMC4227513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.